Legacy Air Rocky Mountain is a pioneering biotech company in Denver, specializing in the development of nasal-spray, self-adjuvanting vaccines for viral respiratory diseases. Their Delta NS1 technology platform is the foundation for the DeltaFLU Universal Influenza Vaccine, currently in Phase 2 clinical development to provide broad protection against all strains of influenza.
With a focus on innovation and public health, Legacy Air Rocky Mountain is also working on the Delta-19 Covid-19 Universal Influenza combination vaccine to combat the dual threat of SARS-CoV-2 and influenza pandemics. Their cutting-edge approach aims to address the evolving challenges of infectious diseases with advanced vaccine solutions.
Generated from their website's infomation